Compass Therapeutics, Inc. (CMPX)
NASDAQ:CMPX
Want to see CMPX full AI Analyst Report?
CMPX Stock Chart & Stats
$6.00
$0.48(33.57%)
At close: 4:00 PM EST
$6.00
$0.48(33.57%)
Day’s Range― - ―
52-Week Range$1.61 - $6.88
Previous CloseN/A
Volume16.21M
Average Volume (3M)5.58M
Market Cap
$365.58M
Enterprise Value$283.74M
Total Cash (Recent Filing)$194.69M
Total Debt (Recent Filing)$9.79M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Aug 05, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding180,087,920
10 Day Avg. Volume3,571,469
30 Day Avg. Volume5,577,408
Financial Highlights & Ratios
PEG Ratio-0.76
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-384.48
Enterprise Value/Ebitda-4.23
Forecast
1Y Price Target
$9.38Price Target Upside56.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.44
Revenue Forecast (FY)-$1.16M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityVery low debt-to-equity (~0.05) and meaningful equity provide durable financial flexibility for a pre-revenue biotech. This reduces near-term bankruptcy risk, supports financing optionality for clinical programs, and lengthens runway compared with highly leveraged peers.
Positive Phase 2/3 Clinical ResultsStatistically significant PFS and improved ORR from the COMPANION-002 trial materially strengthen tovecimig's regulatory and commercial prospects in second-line biliary tract cancer. Durable clinical efficacy and tolerability improve likelihood of partnerships, label discussions, and eventual revenue pathways.
Governance And Shareholder SupportShareholder backing of directors, auditor ratification, and advisory approval of pay signals governance continuity and oversight. Strong governance reduces execution risk for complex development and regulatory processes and supports consistent strategic decision-making over the medium term.
Bears Say
Sizable Cash BurnOperating cash outflows near -$53M TTM reflect high program spending without product revenue. Persistent burn increases the probability the company must access capital markets within months, raising dilution risk and potentially delaying clinical milestones if funding tightens.
Worsening Cash Flow TrendA deteriorating cash-flow trajectory (from -$40.6M in 2023 to -$53.2M TTM) signals increasing program spend or lower operating efficiency. This trend strains runway and heightens reliance on external financing, which can constrain strategic timing for trials and regulatory interactions.
Pre-Revenue And Negative ReturnsWith essentially zero recurring revenue and TTM net losses of -$68M, returns on invested capital are negative. Until regulatory approvals or durable partnerships generate revenue, the company remains structurally dependent on financing, limiting its ability to self-sustain development programs.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics, Inc.’s price range in the past 12 months?
Compass Therapeutics, Inc. lowest stock price was $1.61 and its highest was $6.88 in the past 12 months.
What is Compass Therapeutics, Inc.’s market cap?
Compass Therapeutics, Inc.’s market cap is $365.58M.
When is Compass Therapeutics, Inc.’s upcoming earnings report date?
Compass Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 50 days.
How were Compass Therapeutics, Inc.’s earnings last quarter?
Compass Therapeutics, Inc. released its earnings results on May 05, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.098 by -$0.002.
Is Compass Therapeutics, Inc. overvalued?
According to Wall Street analysts Compass Therapeutics, Inc.’s price is currently Undervalued.
Does Compass Therapeutics, Inc. pay dividends?
Compass Therapeutics, Inc. does not currently pay dividends.
What is Compass Therapeutics, Inc.’s EPS estimate?
Compass Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Compass Therapeutics, Inc. have?
Compass Therapeutics, Inc. has 180,087,920 shares outstanding.
What happened to Compass Therapeutics, Inc.’s price movement after its last earnings report?
Compass Therapeutics, Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.098. Following the earnings report the stock price went up 0.515%.
Which hedge fund is a major shareholder of Compass Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CMPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compass Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.38 (56.25% Upside)
$9.38 (56.25% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.76%
12-Months-Change
Fundamentals
Return on Equity
-39.75%
Trailing 12-Months
Asset Growth
56.08%
Trailing 12-Months
Company Description
Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
CMPX Stock 12 Month Forecast
Average Price Target
$9.38
▲(56.25% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
12.74% Insiders
7.10% Mutual Funds
67.57% Other Institutional Investors
2.32% Public Companies and
Individual Investors